文献速递临床试验与 GCP

持续葡萄糖监测对使用胰岛素注射的1型糖尿病成人血糖控制的影响:DIAMOND随机临床试验

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

该随机临床试验在美国24家内分泌诊所纳入158例使用每日多次胰岛素注射、HbA1c 7.5%至9.9%的1型糖尿病成人,按2:1随机分为持续葡萄糖监测(CGM)组105例和常规护理组53例。24周时,CGM组HbA1c较基线平均降幅大于常规护理组,校正后组间差值为-0.6%(95%CI,-0.8%至-0.3%;P<.001),CGM组低血糖持续时间中位数也较短。

要点

  • CGM组24周HbA1c较基线平均降低1.0%,常规护理组降低0.4%。
  • 24周时校正后HbA1c变化组间差值为-0.6%(95%CI,-0.8%至-0.3%;P<.001)。
  • CGM组血糖低于70 mg/dL的低血糖持续时间中位数43 min/d,常规护理组80 min/d(P=.002)。

核心结论

  • 在使用每日多次胰岛素注射的1型糖尿病成人中,与常规护理相比,使用CGM在24周内使HbA1c水平出现更大降幅。
  • 需要进一步研究评估更长期的有效性以及临床结局和不良反应。

研究设计与样本

  • 随机临床试验,2014年10月至2016年在美国24家内分泌诊所开展。
  • 纳入158例使用每日多次胰岛素注射、HbA1c为7.5%至9.9%的1型糖尿病成人,按2:1随机分为CGM组(n=105)和常规护理对照组(n=53)。
  • 主要结局为中心实验室测定的HbA1c从基线至24周的变化差异。
  • 158例随机参与者中155例(98%)完成研究;CGM组93%在6个月时每周使用CGM至少6天。

主要发现

  • CGM组HbA1c较基线平均降低12周时为1.1%、24周时为1.0%;常规护理组分别降低0.5%和0.4%(重复测量模型P<.001)。
  • 24周时,校正后HbA1c较基线平均变化的组间差值为-0.6%(95%CI,-0.8%至-0.3%;P<.001)。
  • 血糖低于70 mg/dL的低血糖持续时间中位数:CGM组43 min/d(IQR,27-69) vs 常规护理组80 min/d(IQR,36-111)(P=.002)。
  • 严重低血糖事件在CGM组和常规护理组各发生2例。

局限性

  • 需要进一步研究评估更长期的有效性以及临床结局和不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous clinical trials showing the benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly have included adults using insulin pumps, even though the majority of adults with type 1 diabetes administer insulin by injection. OBJECTIVE: To determine the effectiveness of CGM in adults with type 1 diabetes treated with insulin injections. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted between October 2014 and May 2016 at 24 endocrinology practices in the United States that included 158 adults with type 1 diabetes who were using multiple daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%. INTERVENTIONS: Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53). MAIN OUTCOMES AND MEASURES: Primary outcome measure was the difference in change in central-laboratory-measured HbA1c level from baseline to 24 weeks. There were 18 secondary or exploratory end points, of which 15 are reported in this article, including duration of hypoglycemia at less than 70 mg/dL, measured with CGM for 7 days at 12 and 24 weeks. RESULTS: Among the 158 randomized participants (mean age, 48 years [SD, 13]; 44% women; mean baseline HbA1c level, 8.6% [SD, 0.6%]; and median diabetes duration, 19 years [interquartile range, 10-31 years]), 155 (98%) completed the study. In the CGM group, 93% used CGM 6 d/wk or more in month 6. Mean HbA1c reduction from baseline was 1.1% at 12 weeks and 1.0% at 24 weeks in the CGM group and 0.5% and 0.4%, respectively, in the control group (repeated-measures model P < .001). At 24 weeks, the adjusted treatment-group difference in mean change in HbA1c level from baseline was -0.6% (95% CI, -0.8% to -0.3%; P < .001). Median duration of hypoglycemia at less than <70 mg/dL was 43 min/d (IQR, 27-69) in the CGM group vs 80 min/d (IQR, 36-111) in the control group (P = .002). Severe hypoglycemia events occurred in 2 participants in each group. CONCLUSIONS AND RELEVANCE: Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks. Further research is needed to assess longer-term effectiveness, as well as clinical outcomes and adverse effects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02282397.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017. PMID: 28118453. doi:10.1001/jama.2016.19975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。